MedTrace Logo

The Cxbladder Rule-out of Recurrent Urothelial Carcinoma

NCT03673202 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2019-08-14

No results posted yet for this study

Summary

This observational study is designed to collect urine and relevant clinical information from patients who have a known diagnosis of bladder cancer and currently on clinically driven surveillance. The study aims to compare the urine test to the flexible cystoscopy procedure (which the patient is already scheduled).

Conditions

Interventions

DIAGNOSTIC_TEST

Cx bladder Monitor test

Cxbladder Monitor is a non-invasive UC detection test measuring five messenger RNA (mRNA) biomarkers present at elevated levels in patients presenting with urothelial carcinoma and also two clinical variables (whether the previous tumor was primary or recurrent and the time since the previous tumor was resected).

Sponsors & Collaborators

  • Pacific Edge Limited

    collaborator INDUSTRY

  • London Health Sciences Centre

    lead OTHER

Principal Investigators

  • Jonathan Izawa, MD · Schulich School of Medicine and Dentistry

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-26
Primary Completion
2019-08-31
Completion
2020-11-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03673202 on ClinicalTrials.gov